Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib with or without pleurodesis for malignant pleural effusion in EGFR-mutant non-small cell lung cancer
ChiCTR2000036856Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) and malignant pleural effusion (MPE) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Intrapleural objective response rate. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)malignant pleural effusion (MPE)
Beyond the preview
Go deeper on ChiCTR2000036856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036856.